Category: Future Perspectives

Cybersecurity in Healthcare: A Must Have in Today’s Digital World

The healthcare industry has been amongst the prime targets for hackers over the last several years. In 2017, the healthcare industry had been compromised a number of times, representing 25% of the total number of breaches worldwide. Across these instances, around 31 million records were compromised, stolen or lost. In order to overcome these challenges,

New Frontiers in Cancer Therapies: Focus on Transcription Factors, GTPases, Phosphatases and GPCRs, 2018-2030

Cancer Therapies continues to be one of the most active segments within the pharmaceutical industry. However, certain biological targets have long eluded drug development efforts. One such target is Ras family, which has been identified to play a critical role in oncogenesis. Scientific literature suggests that the RAS gene is mutated across about 30% of

Novel Spectrometry Platforms: Key Advancements

Spectrometry is an analytical technique that is used to analyze the fundamental components of a radiation or ion beam’s spectrum. There are two main divisions of spectrometry, which involve the use of electromagnetic radiation and ionization (also known as mass spectrometry), respectively. The former division of spectrometry uses electromagnetic radiation from different regions of an

T Cells: The Future Roadmap of The USD 15 Billion+ Opportunity

Although cancer therapeutics continue to be one of the most active areas in terms of drug development, there is still a significant unmet need in this domain. Conventional cancer treatments, such as chemotherapy, surgery and radiation therapy, have demonstrated very limited efficacy in late-stage cancers. Amidst the current initiatives to develop more targeted anti-cancer therapies,

Cell Therapy Manufacturing: The $ 8 Billion+ Growth Opportunity

Cell Therapy Manufacturing market has gained significant attention in the overall biopharmaceutical industry. The personalized nature of these cell therapies options render them highly specific and, according to a number of clinical studies, safe and efficacious. Around 20 such therapies have been approved so far; recent approvals include Alofisel® (2018), YESCARTA® (2017) and Kymriah® (2017).

Gene Therapies: Mapping the Future Growth Potential

The first gene therapy, Gendicine®, was only approved in 2003 in China; since then, the domain has evolved significantly. The ‘Gene Therapy Market (2nd Edition), 2018-2030’ report provides an extensive study on the current market landscape of gene therapies, with a prime focus on gene augmentation based therapies and oncolytic viral therapies, featuring an elaborate discussion on

Respiratory Disorders: Mapping the Future Potential

The World Health Organization (WHO) estimates the global prevalence of two of the most common chronic respiratory disorders, namely asthma and chronic obstructive pulmonary disease (COPD), to be around 335 million and 400 million patients respectively. According to the data provided by the WHO, more than 3 million people die annually from COPD. Asthma, on

Back of the Eye Disorders: Novel Drugs and Delivery Technologies

The current treatment landscape for back of the eye disorders is characterized by the presence of blockbuster novel ophthalmic drugs, such as Lucentis® and Eylea®, and various other therapeutic options. Despite the success of these therapies, their invasive mode of administration, high dosage frequency and other drug related side effects, are some of the drawbacks

Microbiome Therapeutics and Diagnostics: Unlocking the Future Potential

Microbiome therapeutics represent a new frontier in the field of medicine. Currently, there are many probiotics, prebiotics, and medical foods and supplements that are commercially available, and several drug / therapy candidates that claim to be capable of modifying / manipulating the microbiome in order to provide therapeutic benefits. The ‘Human Microbiome Market’ report provides a comprehensive study on the current